To Evaluate the Safety and Efficacy of Hunterase(Idursulfase-beta) in Hunter Syndrome Patients less than 6 Years of Age Receiving Idursulfase Enzyme Replacement Therapy

Trial Profile

To Evaluate the Safety and Efficacy of Hunterase(Idursulfase-beta) in Hunter Syndrome Patients less than 6 Years of Age Receiving Idursulfase Enzyme Replacement Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Idursulfase (Primary)
  • Indications Mucopolysaccharidosis II
  • Focus Adverse reactions
  • Sponsors GC Pharma; Green Cross
  • Most Recent Events

    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma
    • 24 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top